{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:50:23Z","timestamp":1760953823418},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioData Mining"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13040-016-0097-1","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T04:20:04Z","timestamp":1464236404000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Data integration to prioritize drugs using genomics and curated data"],"prefix":"10.1186","volume":"9","author":[{"given":"Riku","family":"Louhimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Belitskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Klefstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sampsa","family":"Hautaniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"97_CR1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"97_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov. 2010; 9:203\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"97_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/gm326","volume":"4","author":"YY Li","year":"2012","unstructured":"Li YY, Jones S. Drug repositioning for personalized medicine. Genome Med. 2012; 4:27.","journal-title":"Genome Med"},{"key":"97_CR4","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-07-4531","volume":"14","author":"R Simon","year":"2008","unstructured":"Simon R. The use of genomics in clinical trial design. Clin Cancer Res. 2008; 14:5984\u2013993.","journal-title":"Clin Cancer Res"},{"key":"97_CR5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMp1014256","volume":"364","author":"U McDermott","year":"2011","unstructured":"McDermott U, Downing JR, et al. Genomics and the continuum of cancer care. N Engl J Med. 2011; 364:340\u201350.","journal-title":"N Engl J Med"},{"key":"97_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","volume":"145","author":"DA Haber","year":"2011","unstructured":"Haber DA, Gray NS, et al. The evolving war on cancer. Cell. 2011; 145:19\u201324.","journal-title":"Cell"},{"key":"97_CR7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrclinonc.2010.227","volume":"8","author":"L Hood","year":"2011","unstructured":"Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011; 8:184\u20137.","journal-title":"Nat Rev Clin Oncol"},{"key":"97_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMp1114866","volume":"366","author":"R Mirnezami","year":"2012","unstructured":"Mirnezami R, Nicholson J, et al. Preparing for precision medicine. N Engl J Med. 2012; 366:489\u201391.","journal-title":"N Engl J Med"},{"issue":"9","key":"97_CR9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nbt.2345","volume":"30","author":"P Creixell","year":"2012","unstructured":"Creixell P, Schoof EM, et al. Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol. 2012; 30(9):842\u20138.","journal-title":"Nat Biotechnol"},{"key":"97_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc3721","volume":"14","author":"VN Kristensen","year":"2014","unstructured":"Kristensen VN, Lingj\u00e6rde OC, et al. Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer. 2014; 14:299\u2013313.","journal-title":"Nat Rev Cancer"},{"key":"97_CR11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","volume":"148","author":"R Chen","year":"2012","unstructured":"Chen R, Mias G, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012; 148:1293\u20131307.","journal-title":"Cell"},{"key":"97_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nmeth.1893","volume":"9","author":"R Louhimo","year":"2012","unstructured":"Louhimo R, Lepikhova T, et al. Comparative analysis of algorithms for integration of copy number and expression data. Nat Methods. 2012; 9:351\u20135.","journal-title":"Nat Methods"},{"key":"97_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","volume":"12","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Deshpande T, et al. Exploiting drug\u2013disease relationships for computational drug repositioning. Brief Bioinform. 2011; 12:303\u201311.","journal-title":"Brief Bioinform"},{"key":"97_CR14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2013.1","volume":"93","author":"M Hurle","year":"2013","unstructured":"Hurle M, Yang L, et al. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013; 93:335\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"97_CR15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"G Jin","year":"2014","unstructured":"Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014; 19:637\u201344.","journal-title":"Drug Discov Today"},{"key":"97_CR16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/0008-5472.CAN-12-3122","volume":"73","author":"DL Masica","year":"2013","unstructured":"Masica DL, Karchin R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res. 2013; 73:1699\u20131708.","journal-title":"Cancer Res"},{"key":"97_CR17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"The Cancer Genome Atlas Research Network","year":"2008","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061\u20138.","journal-title":"Nature"},{"key":"97_CR18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Network","year":"2011","unstructured":"The Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609\u201315.","journal-title":"Nature"},{"key":"97_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61\u201370.","journal-title":"Nature"},{"key":"97_CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bioinformatics\/btr709","volume":"28","author":"R Kolde","year":"2012","unstructured":"Kolde R, Laur S, et al. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28:573\u201380.","journal-title":"Bioinformatics"},{"key":"97_CR21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nbt1203","volume":"24","author":"S Aerts","year":"2006","unstructured":"Aerts S, Lambrechts D, et al. Gene prioritization through genomic data fusion. Nat Biotechnol. 2006; 24:537\u201344.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"97_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"D Botstein","year":"2000","unstructured":"Botstein D, Cherry J, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000; 25(1):25\u20139.","journal-title":"Nat Genet"},{"key":"97_CR23","doi-asserted-by":"crossref","first-page":"bau126","DOI":"10.1093\/database\/bau126","volume":"2015","author":"S Chowdhury","year":"2015","unstructured":"Chowdhury S, Sarkar RR. Comparison of human cell signaling pathway databases \u2014 evolution, drawbacks and challenges. Database. 2015; 2015:bau126.","journal-title":"Database"},{"issue":"Suppl 7","key":"97_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2164-16-S7-S18","volume":"16","author":"N Nguyen","year":"2015","unstructured":"Nguyen N, Lindsey M, et al. Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses. BMC Genom. 2015; 16(Suppl 7):18.","journal-title":"BMC Genom"},{"key":"97_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330\u20137.","journal-title":"Nature"},{"key":"97_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/gm186","volume":"2","author":"K Ovaska","year":"2010","unstructured":"Ovaska K, Laakso M, et al. Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med. 2010; 2:65.","journal-title":"Genome Med"},{"key":"97_CR27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/bioinformatics\/btr019","volume":"27","author":"R Louhimo","year":"2011","unstructured":"Louhimo R, Hautaniemi S. CNAmet: an R package for integration of copy number, expression and methylation data. Bioinformatics. 2011; 27:887\u20138.","journal-title":"Bioinformatics"},{"issue":"1","key":"97_CR28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12885-015-1265-2","volume":"15","author":"C Liu","year":"2015","unstructured":"Liu C, Louhimo R, et al. Identification of sample-specific regulations using integrative network level analysis. BMC Cancer. 2015; 15(1):319.","journal-title":"BMC Cancer"},{"key":"97_CR29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463:899\u2013905.","journal-title":"Nature"},{"key":"97_CR30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrc1299","volume":"4","author":"PA Futreal","year":"2004","unstructured":"Futreal PA, Coin L, et al. A census of human cancer genes. Nat Rev Cancer. 2004; 4:177\u201383.","journal-title":"Nat Rev Cancer"},{"key":"97_CR31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes SA, Bindal N, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39:945.","journal-title":"Nucleic Acids Res"},{"key":"97_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2771","volume":"10","author":"T Santarius","year":"2010","unstructured":"Santarius T, Shipley J, et al. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010; 10:59\u201364.","journal-title":"Nat Rev Cancer"},{"key":"97_CR33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Xiang HFZ, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009; 459:1005.","journal-title":"Nature"},{"key":"97_CR34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001; 29:1165\u201388.","journal-title":"Ann Stat"},{"key":"97_CR35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/nar\/gkp896","volume":"38","author":"M Kanehisa","year":"2010","unstructured":"Kanehisa M, Goto S, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010; 38:355\u201360.","journal-title":"Nucleic Acids Res"},{"key":"97_CR36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/nar\/gkq1126","volume":"39","author":"C Knox","year":"2011","unstructured":"Knox C, Law V, et al. Drugbank 3.0: a comprehensive resource for \u2018omics\u2019 research on drugs. Nucleic Acids Res. 2011; 39:1035\u201341.","journal-title":"Nucleic Acids Res"},{"key":"97_CR37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/bioinformatics\/btq277","volume":"26","author":"M Laakso","year":"2010","unstructured":"Laakso M, Hautaniemi S. Integrative platform to translate gene sets to networks. Bioinformatics. 2010; 26:1802\u20133.","journal-title":"Bioinformatics"},{"issue":"2","key":"97_CR38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1101\/gr.124347.111","volume":"22","author":"JD Brooks","year":"2012","unstructured":"Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res. 2012; 22(2):183\u20137.","journal-title":"Genome Res"},{"key":"97_CR39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med. 2007; 357:39\u201351.","journal-title":"N Engl J Med"},{"key":"97_CR40","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98:10869\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"97_CR41","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"97_CR42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/ERC-12-0060","volume":"19","author":"M Tenhagen","year":"2012","unstructured":"Tenhagen M, van Diest PJ, et al. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer. 2012; 19:115\u201329.","journal-title":"Endocr Relat Cancer"},{"key":"97_CR43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","volume":"25","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann R, Rodon J, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014; 25:552\u201363.","journal-title":"Ann Oncol"},{"key":"97_CR44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH, et al. A small molecule\u2013kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23:329\u201336.","journal-title":"Nat Biotechnol"},{"key":"97_CR45","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, et al. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18:1855\u201362.","journal-title":"Clin Cancer Res"},{"key":"97_CR46","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","volume":"19","author":"F Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 F, Bachelot T, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013; 19:3693\u2013702.","journal-title":"Clin Cancer Res"},{"key":"97_CR47","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, et al. Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32:2255\u2013269.","journal-title":"J Clin Oncol"},{"key":"97_CR48","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ijc.26304","volume":"130","author":"DC Tomlinson","year":"2012","unstructured":"Tomlinson DC, Knowles MA, et al. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer. 2012; 130:2857\u2013866.","journal-title":"Int J Cancer"},{"key":"97_CR49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1677\/ERC-07-0080","volume":"15","author":"D Meijer","year":"2008","unstructured":"Meijer D, Sieuwerts AM, et al. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer. 2008; 15:101\u201311.","journal-title":"Endocr Relat Cancer"},{"key":"97_CR50","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/0008-5472.CAN-13-2779","volume":"74","author":"MJ Sikora","year":"2014","unstructured":"Sikora MJ, Cooper KL, et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014; 74:1463\u201374.","journal-title":"Cancer Res"},{"key":"97_CR51","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-12-1248","volume":"72","author":"B Ramaswamy","year":"2012","unstructured":"Ramaswamy B, Lu Y, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K\/AKT pathway. Cancer Res. 2012; 72:5048\u2013059.","journal-title":"Cancer Res"},{"key":"97_CR52","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1093\/annonc\/mdt217","volume":"24","author":"WJ Gradishar","year":"2013","unstructured":"Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013; 24:2492\u2013500.","journal-title":"Ann Oncol"},{"key":"97_CR53","doi-asserted-by":"crossref","first-page":"63038","DOI":"10.1371\/journal.pone.0063038","volume":"8","author":"LJ Leon","year":"2013","unstructured":"Leon LJ, Pasupuleti N, et al. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells. PloS ONE. 2013; 8:63038.","journal-title":"PloS ONE"},{"key":"97_CR54","doi-asserted-by":"crossref","unstructured":"Rowson-Hodel A, Berg A, et al. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Lett. 2016. doi: 10.1016\/j.canlet.2016.02.042 .","DOI":"10.1016\/j.canlet.2016.02.042"},{"key":"97_CR55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2011.11.023","volume":"317","author":"G Lauritzen","year":"2012","unstructured":"Lauritzen G, Stock CM, et al. The Na+\/H+ exchanger NHE1, but not the Na+, cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. Cancer Lett. 2012; 317:172\u201383.","journal-title":"Cancer Lett"},{"key":"97_CR56","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00432-011-1039-4","volume":"137","author":"J Cicenas","year":"2011","unstructured":"Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011; 137:1409\u201318.","journal-title":"J Cancer Res Clin Oncol"},{"key":"97_CR57","first-page":"4152","volume":"5","author":"T Kusume","year":"1999","unstructured":"Kusume T, Tsuda H, et al. The p16-Cyclin D1\/CDK4-pRb pathway and clinical outcome in Epithelial ovarian cancer. Clin Cancer Res. 1999; 5:4152\u2013157.","journal-title":"Clin Cancer Res"},{"key":"97_CR58","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd3908","volume":"11","author":"M Guha","year":"2012","unstructured":"Guha M. Cyclin-dependent kinase inhibitors move into phase III. Nat Rev Drug Discov. 2012; 11:892\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"97_CR59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1078-0432.OVCA13-B48","volume":"19","author":"B Taylor-Harding","year":"2013","unstructured":"Taylor-Harding B, Agadjanian H, et al. Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer. Clin Cancer Res. 2013; 19:48.","journal-title":"Clin Cancer Res"},{"key":"97_CR60","doi-asserted-by":"crossref","unstructured":"Wiedemeyer WR, Beach JA, et al. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol. 2014;4.","DOI":"10.3389\/fonc.2014.00034"},{"issue":"D1","key":"97_CR61","doi-asserted-by":"crossref","first-page":"D914","DOI":"10.1093\/nar\/gku935","volume":"43","author":"AP Davis","year":"2015","unstructured":"Davis AP, Grondin CJ, et al. The Comparative Toxicogenomics Database\u2019s 10th year anniversary: update 2015. Nucleic Acids Res. 2015; 43(D1):D914\u2013D920.","journal-title":"Nucleic Acids Res"},{"key":"97_CR62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ygeno.2006.06.016","volume":"88","author":"T Haitina","year":"2006","unstructured":"Haitina T, Lindblom J, et al. Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics. 2006; 88:779\u201390.","journal-title":"Genomics"},{"key":"97_CR63","first-page":"911","volume":"73","author":"J Hooijberg","year":"2014","unstructured":"Hooijberg J, Jansen G, et al. Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). Cancer Chemother Pharmacol. 2014; 73:911\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"97_CR64","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, et al. Tissue-based map of the human proteome. Science. 2015; 347:1260419.","journal-title":"Science"}],"container-title":["BioData Mining"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13040-016-0097-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T04:53:02Z","timestamp":1600663982000},"score":1,"resource":{"primary":{"URL":"http:\/\/biodatamining.biomedcentral.com\/articles\/10.1186\/s13040-016-0097-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1186\/s13040-016-0097-1","relation":{},"ISSN":["1756-0381"],"issn-type":[{"value":"1756-0381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]},"article-number":"21"}}